# Shanghai YingLi Pharmaceutical Co. Ltd. trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shanghai YingLi Pharmaceutical Co. Ltd.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-yingli-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07903207 | First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of... | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumors, Ovarian | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903207) |
| January 16, 2025 | NCT06779045 | A Study of AK-1286 in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumor | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06779045) |
| October 29, 2024 | NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Not yet recruiting | Metastatic Pancreatic Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662669) |
| August 12, 2024 | NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2/3 | Not yet recruiting | Peripheral T Cell Lymphoma | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548347) |
| April 3, 2024 | NCT06343935 | A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 4 | Unknown | Indolent B-cell Lymphoma | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06343935) |
| October 24, 2023 | NCT06096974 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06096974) |
| October 23, 2023 | NCT06094777 | A Study of HY-0102 in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094777) |
| October 12, 2023 | NCT06078800 | A Study of YL-17231 in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06078800) |
| September 7, 2023 | NCT06026501 | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06026501) |
| July 14, 2022 | NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumors | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05457517) |
| June 23, 2022 | NCT05429398 | A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05429398) |
| March 11, 2022 | NCT05274997 | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Peripheral T/NK Cell Lymphoma (R/R PTCL) | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05274997) |
| February 8, 2022 | NCT05228600 | YL-13027 in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Solid Tumor | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05228600) |
| December 30, 2021 | NCT05173805 | Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumor | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05173805) |
| November 15, 2021 | NCT05119933 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumor | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05119933) |
| July 23, 2021 | NCT04975061 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Observational | Unknown | Effectiveness，Safety，Thymic Cancer | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04975061) |
| January 12, 2021 | NCT04705090 | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 | Unknown | PTCL | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04705090) |
| August 5, 2020 | NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1/2 | Unknown | Diffuse Large B Cell Lymphoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04500561) |
| May 7, 2020 | NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Follicular Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04379167) |
| April 30, 2020 | NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Lymphoma, Follicular | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04370405) |
| February 21, 2020 | NCT04279405 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Completed | Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04279405) |
| September 30, 2019 | NCT04108325 | A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Relapsed or Refractory Peripheral T-Cell Lymphoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04108325) |
| August 8, 2019 | NCT04049929 | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04049929) |
| March 11, 2019 | NCT03869632 | First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | Advanced Solid Tumors | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03869632) |
| November 28, 2018 | NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Unknown | B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03757000) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 6 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 18 |
| Not yet recruiting | 5 |
| Recruiting | 1 |
| Completed | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pancreatic Neoplasms | 3 |
| Lymphoma, Follicular | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Recurrence | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Carcinoma, Transitional Cell | 1 |
| Colorectal Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Guatemalan restaurants in the United States](https://specstream.ai/data/businesses/guatemalan-restaurants/united-states)
- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
- [Medical schools in the United States](https://specstream.ai/data/businesses/medical-schools/united-states)
